Unlike most other industries, in science it helps to work with your friends – that’s a quote from Dr. Jonathan Rothbard, CSO of 180 Life Sciences (NASDAQ:ATNF), who joins the podcast with ATNF co-founder Prof Sir Marc Feldmann, who co-founded the company with Professor Raphael Mechoulam (known for his discovery of tetrahydrocannabinol (THC), the psychoactive part […]

From the Stanford University lab of a cancer immunotherapy pioneer to an IPO, a small-but-growing Peninsula biotech company is looking to continue its win streak with its third biopharma collaboration of the year. Bolt Biotherapeutics Inc. of Redwood City said it will partner with drug giant Bristol-Myers Squibb Co. on a new combination of two […]

Cyclacel Pharmaceuticals recently announced the first patient dosed in its Phase 1/2 study of oral fadraciclib in patients with advanced solid tumors and aggressive lymphomas. The trial used a streamlined study design and will determine the recommended Phase 2 dose. Once established, the trial will immediately enter a proof of concept, cohort stage trial with […]